Eric Rubin, MD
Former Senior VP, Clinical Oncology
Merck
Dr. Rubin has focused on cancer drug development for over 35 years, initially as a faculty member at the Dana-Farber Cancer Institute, then as a senior leader of the Cancer Institute of New Jersey, where he served as the Director of the Investigational Therapeutics Division of that institution. Subsequently, he was recruited to Merck, where he led the initial development of the anti-PD-1 antibody pembrolizumab, which was the first anti-PD-1 therapy approved in the U.S., and in the identification of the significant activity of this therapeutic across several cancer types. Dr. Rubin served as a member of National Cancer Institute and American Cancer Society study sections, as well as on program committees for the American Association of Cancer Research and the American Society of Clinical Oncology. He was a co-chair of the Cancer Steering Committee of the Biomarkers Consortium, Foundation of the National Institute of Health, and was a member of the National Cancer Moonshot Initiative/Blue Ribbon Panel Working Group on Expanding Clinical Trials. Dr. Rubin holds an B.S. in mathematics and biology from Tulane University, and an M.D. from the University of South Florida.